ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $10.42 billion. The enterprise value is $11.29 billion.
| Market Cap | 10.42B |
| Enterprise Value | 11.29B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 1.06 billion shares outstanding. The number of shares has increased by 26.61% in one year.
| Current Share Class | 1.06B |
| Shares Outstanding | 1.06B |
| Shares Change (YoY) | +26.61% |
| Shares Change (QoQ) | +2.26% |
| Owned by Insiders (%) | 27.89% |
| Owned by Institutions (%) | 19.81% |
| Float | 406.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 61.82 |
| Forward PS | 38.36 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 67.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.72
| Current Ratio | 5.72 |
| Quick Ratio | 5.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.54% |
| Return on Invested Capital (ROIC) | -69.10% |
| Return on Capital Employed (ROCE) | -45.63% |
| Weighted Average Cost of Capital (WACC) | 4.73% |
| Revenue Per Employee | $239,931 |
| Profits Per Employee | -$1.44M |
| Employee Count | 691 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.26 |
Taxes
| Income Tax | -161,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +294.60% in the last 52 weeks. The beta is 0.03, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | +294.60% |
| 50-Day Moving Average | 8.23 |
| 200-Day Moving Average | 7.36 |
| Relative Strength Index (RSI) | 62.14 |
| Average Volume (20 Days) | 14,115,991 |
Short Selling Information
The latest short interest is 125.41 million, so 11.83% of the outstanding shares have been sold short.
| Short Interest | 125.41M |
| Short Previous Month | 125.64M |
| Short % of Shares Out | 11.83% |
| Short % of Float | 30.84% |
| Short Ratio (days to cover) | 15.07 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $165.79 million and -$992.36 million in losses. Loss per share was -$0.99.
| Revenue | 165.79M |
| Gross Profit | 164.70M |
| Operating Income | -251.80M |
| Pretax Income | -992.58M |
| Net Income | -992.36M |
| EBITDA | -235.30M |
| EBIT | -251.80M |
| Loss Per Share | -$0.99 |
Balance Sheet
The company has $357.37 million in cash and $1.23 billion in debt, with a net cash position of -$871.03 million or -$0.82 per share.
| Cash & Cash Equivalents | 357.37M |
| Total Debt | 1.23B |
| Net Cash | -871.03M |
| Net Cash Per Share | -$0.82 |
| Equity (Book Value) | -1.05B |
| Book Value Per Share | -0.99 |
| Working Capital | 362.25M |
Cash Flow
In the last 12 months, operating cash flow was -$281.14 million and capital expenditures -$6.94 million, giving a free cash flow of -$288.07 million.
| Operating Cash Flow | -281.14M |
| Capital Expenditures | -6.94M |
| Depreciation & Amortization | 16.50M |
| Net Borrowing | 74.96M |
| Free Cash Flow | -288.07M |
| FCF Per Share | -$0.27 |
Margins
| Gross Margin | 99.34% |
| Operating Margin | -151.88% |
| Pretax Margin | -598.69% |
| Profit Margin | n/a |
| EBITDA Margin | -141.92% |
| EBIT Margin | -151.88% |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.61% |
| Shareholder Yield | -26.61% |
| Earnings Yield | -9.68% |
| FCF Yield | -2.81% |
Analyst Forecast
The average price target for ImmunityBio is $12.75, which is 29.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.75 |
| Price Target Difference | 29.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 114.05% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -8.87 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.87 |
| Piotroski F-Score | 3 |